Daubert, M. A., Yow, E., Dunn, G., Barnhart, H., Douglas, P., Udelson, J., … Sabbah, H. (2016). EFFECTS OF A NOVEL TETRAPEPTIDE IN HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PHASE I RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ELAMIPRETIDE. In Journal of the American College of Cardiology (Vol. 67, pp. 1283–1283). Elsevier BV. https://doi.org/10.1016/s0735-1097(16)31284-0

Daubert, Melissa A., Eric Yow, Gary Dunn, Huiman Barnhart, Pamela Douglas, James Udelson, Christopher O’Connor, Sidney Goldstein, and Hani Sabbah. “EFFECTS OF A NOVEL TETRAPEPTIDE IN HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PHASE I RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ELAMIPRETIDE.” In Journal of the American College of Cardiology, 67:1283–1283. Elsevier BV, 2016. https://doi.org/10.1016/s0735-1097(16)31284-0.

Daubert MA, Yow E, Dunn G, Barnhart H, Douglas P, Udelson J, et al. EFFECTS OF A NOVEL TETRAPEPTIDE IN HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PHASE I RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ELAMIPRETIDE. In: Journal of the American College of Cardiology. Elsevier BV; 2016. p. 1283–1283.

Daubert, Melissa A., et al. “EFFECTS OF A NOVEL TETRAPEPTIDE IN HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PHASE I RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ELAMIPRETIDE.” Journal of the American College of Cardiology, vol. 67, no. 13, Elsevier BV, 2016, pp. 1283–1283. Crossref, doi:10.1016/s0735-1097(16)31284-0.

Daubert MA, Yow E, Dunn G, Barnhart H, Douglas P, Udelson J, O’Connor C, Goldstein S, Sabbah H. EFFECTS OF A NOVEL TETRAPEPTIDE IN HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PHASE I RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ELAMIPRETIDE. Journal of the American College of Cardiology. Elsevier BV; 2016. p. 1283–1283.